What is RedDress?
RedDress is a privately held, Israel-based company, with a U.S. subsidiary in Ponte Vedra Beach, Florida. Established in 2009, the company is dedicated to pioneering more effective, natural, and economically viable treatments for chronic wounds. Its core innovation, ActiGraft, represents a significant advancement in patient care and therapeutic solutions within the medical technology sector. The company's focus on chronic wound management underscores its commitment to improving patient outcomes and addressing a critical healthcare need.
How much funding has RedDress raised?
RedDress has raised a total of $26M across 1 funding round:
Series D
$26M
Series D (2023): $26M with participation from HCS Capital Partners
Key Investors in RedDress
HCS Capital Partners
HCS Capital Partners is a venture capital firm based in Miami, specializing in technology-driven companies across North America and Israel. They focus on providing strategic support in technology, globalization, and marketing to help portfolio companies scale rapidly.
What's next for RedDress?
The recent major strategic investment suggests RedDress is entering a phase of accelerated scaling and market penetration. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and expand its commercial reach. Strategic partnerships and broader adoption of ActiGraft are likely next steps as the company solidifies its position in the competitive wound care market. The enterprise-level funding context points towards a mature stage of development, focused on market leadership and profitability.
See full RedDress company page
